株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

鎌状赤血球病治療薬のパイプライン分析

Sickle Cell Disease Drug Development Pipeline Review, 2017

発行 GlobalData 商品コード 588365
出版日 ページ情報 英文 77 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.59円で換算しております。
Back to Top
鎌状赤血球病治療薬のパイプライン分析 Sickle Cell Disease Drug Development Pipeline Review, 2017
出版日: 2017年11月17日 ページ情報: 英文 77 Pages
概要

当レポートでは、鎌状赤血球病 (およびそれに伴う血管閉塞症) の治療薬の治験・開発動向について分析し、疾患の概要や、現在までの治療薬の開発・上市状況、現在治験中/審査中の主要なパイプライン製品の一覧、休止中・中止済みプロジェクトの概略、今後の治験の方向性や実現見通しなどについて調査しております。

第1章 目次

第2章 イントロダクション

  • 分析範囲
  • 鎌状赤血球病:概要
  • 鎌状赤血球症に伴う血管閉塞症:概要

第3章 治療薬の開発

  • 鎌状赤血球病
  • 鎌状赤血球症に伴う血管閉塞症

第4章 治療薬の評価

  • 鎌状赤血球病
  • 鎌状赤血球症に伴う血管閉塞症

第5章 治療薬の開発に参加している企業

  • 鎌状赤血球病
  • 鎌状赤血球症に伴う血管閉塞症

第6章 現在休止中のプロジェクト

  • 鎌状赤血球病
  • 鎌状赤血球症に伴う血管閉塞症

第7章 開発が中止されたプロジェクト

  • 鎌状赤血球症に伴う血管閉塞症

第8章 製品開発のマイルストーン

  • 鎌状赤血球病
  • 鎌状赤血球症に伴う血管閉塞症

第9章 付録

目次
Product Code: GBIHC025IDB

Executive Summary

Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain and frequent infections. There are a total of 62 products in development for this indication, by 45 companies and nine academic institutions.

Key companies operating in this pipeline space include Acceleron Pharma, Epidestiny, Errant Gene Therapeutics, Gamida Cell, Global Blood Therapeutics, Hillhurst Biopharmaceuticals, Novartis and Regenacy Pharmaceuticals. Hemoglobin and a range of histone deacetylases are the most common molecular targets being studied in sickle cell anemia.

Vaso-occlusive crisis associated with sickle cell disease is a painful episode that occurs in people who have sickle cell anemia. Symptoms include fever, pain, fatigue, abdominal pain and swelling, headaches, shortness of breath, dehydration and infection. There are a total of 10 products in development for this indication, by nine companies.

This report provides an overview of the Sickle Cell Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for sickle cell anemia and vaso-occlusive crisis associated with sickle cell disease, and features dormant and discontinued projects.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

1 Table of Contents

1 Table of Contents 4

  • 1.1 List of Tables 5
  • 1.2 List of Figures 6

2 Introduction 7

  • 2.1 Sickle Cell Disease Report Coverage 7
  • 2.2 Sickle Cell Disease - Overview 7
  • 2.3 Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Overview 7

3 Therapeutics Development 8

  • 3.1 Sickle Cell Disease 8
  • 3.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease 15

4 Therapeutics Assessment 18

  • 4.1 Sickle Cell Disease 18
  • 4.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease 25

5 Companies Involved in Therapeutics Development 31

  • 5.1 Sickle Cell Disease 31
  • 5.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease 47

6 Dormant Projects 52

  • 6.1 Sickle Cell Disease 52
  • 6.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease 54

7 Discontinued Products 55

  • 7.1 Vaso-Occlusive Crisis Associated With Sickle Cell Disease 55

8 Product Development Milestones 56

  • 8.1 Sickle Cell Disease 56
  • 8.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease 67

9 Appendix 76

  • 9.1 Methodology 76
  • 9.2 Coverage 76
  • 9.3 Secondary Research 76
  • 9.4 Primary Research 76
  • 9.5 Expert Panel Validation 76
  • 9.6 Contact Us 77
  • 9.7 Disclaimer 77

1.1 List of Tables

  • Table 1: Number of Products under Development for Sickle Cell Disease 8
  • Table 2: Number of Products under Development by Companies, Sickle Cell Disease 9
  • Table 3: Number of Products under Development by Universities/Institutes, Sickle Cell Disease 11
  • Table 4: Products under Development by Companies, Sickle Cell Disease 12
  • Table 5: Products under Development by Universities/Institutes, Sickle Cell Disease 14
  • Table 6: Number of Products under Development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease 15
  • Table 7: Number of Products under Development by Companies, Vaso-Occlusive Crisis Associated With Sickle Cell Disease 16
  • Table 8: Products under Development by Companies, Vaso-Occlusive Crisis Associated With Sickle Cell Disease 17
  • Table 9: Number of Products by Stage and Target, Sickle Cell Disease 19
  • Table 10: Number of Products by Stage and Mechanism of Action, Sickle Cell Disease 21
  • Table 11: Number of Products by Stage and Route of Administration, Sickle Cell Disease 23
  • Table 12: Number of Products by Stage and Molecule Type, Sickle Cell Disease 24
  • Table 13: Number of Products by Stage and Target, Vaso-Occlusive Crisis Associated With Sickle Cell Disease 26
  • Table 14: Number of Products by Stage and Mechanism of Action, Vaso-Occlusive Crisis Associated With Sickle Cell Disease 27
  • Table 15: Number of Products by Stage and Route of Administration, Vaso-Occlusive Crisis Associated With Sickle Cell Disease 29
  • Table 16: Number of Products by Stage and Molecule Type, Vaso-Occlusive Crisis Associated With Sickle Cell Disease 30
  • Table 17: Sickle Cell Disease - Pipeline by Acceleron Pharma Inc 31
  • Table 18: Sickle Cell Disease - Pipeline by Addmedica SAS 31
  • Table 19: Sickle Cell Disease - Pipeline by Angiocrine Bioscience Inc 32
  • Table 20: Sickle Cell Disease - Pipeline by Annexin Pharmaceuticals AB 32
  • Table 21: Sickle Cell Disease - Pipeline by ArQule Inc 33
  • Table 22: Sickle Cell Disease - Pipeline by Bio Products Laboratory Ltd 33
  • Table 23: Sickle Cell Disease - Pipeline by Bioverativ Inc 34
  • Table 24: Sickle Cell Disease - Pipeline by bluebird bio Inc 35
  • Table 25: Sickle Cell Disease - Pipeline by Bristol-Myers Squibb Co 35
  • Table 26: Sickle Cell Disease - Pipeline by Calimmune Inc 36
  • Table 27: Sickle Cell Disease - Pipeline by CRISPR Therapeutics 36
  • Table 28: Sickle Cell Disease - Pipeline by CSL Ltd 37
  • Table 29: Sickle Cell Disease - Pipeline by Daiichi Sankyo Co Ltd 37
  • Table 30: Sickle Cell Disease - Pipeline by Editas Medicine Inc 38
  • Table 31: Sickle Cell Disease - Pipeline by Errant Gene Therapeutics LLC 38
  • Table 32: Sickle Cell Disease - Pipeline by Gamida Cell Ltd 38
  • Table 33: Sickle Cell Disease - Pipeline by Genethon SA 39
  • Table 34: Sickle Cell Disease - Pipeline by Gilead Sciences Inc 39
  • Table 35: Sickle Cell Disease - Pipeline by Global Blood Therapeutics Inc 40
  • Table 36: Sickle Cell Disease - Pipeline by Incyte Corp 40
  • Table 37: Sickle Cell Disease - Pipeline by Ironwood Pharmaceuticals Inc 41
  • Table 38: Sickle Cell Disease - Pipeline by La Jolla Pharmaceutical Company 41
  • Table 39: Sickle Cell Disease - Pipeline by MaxCyte Inc 42
  • Table 40: Sickle Cell Disease - Pipeline by Merck & Co Inc 43
  • Table 41: Sickle Cell Disease - Pipeline by Morphogenesis Inc 43
  • Table 42: Sickle Cell Disease - Pipeline by NKT Therapeutics Inc 43
  • Table 43: Sickle Cell Disease - Pipeline by Novartis AG 44
  • Table 44: Sickle Cell Disease - Pipeline by Orphagen Pharmaceuticals Inc 44
  • Table 45: Sickle Cell Disease - Pipeline by Prolong Pharmaceuticals LLC 45
  • Table 46: Sickle Cell Disease - Pipeline by Protagonist Therapeutics Inc 45
  • Table 47: Sickle Cell Disease - Pipeline by ReveraGen BioPharma Inc 46
  • Table 48: Sickle Cell Disease - Pipeline by Sancilio & Company Inc 46
  • Table 49: Sickle Cell Disease - Pipeline by Sangamo Therapeutics Inc 46
  • Table 50: Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by AstraZeneca Plc 47
  • Table 51: Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Bristol-Myers Squibb Co 48
  • Table 52: Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Gilead Sciences Inc 48
  • Table 53: Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Modus Therapeutics Holding AB 49
  • Table 54: Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Novartis AG 49
  • Table 55: Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by NuvOx Pharma LLC 50
  • Table 56: Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Pfizer Inc 50
  • Table 57: Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Prolong Pharmaceuticals LLC 51
  • Table 58: Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Seattle Genetics Inc 51
  • Table 59: Sickle Cell Disease - Dormant Projects 52
  • Table 60: Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Dormant Projects 54
  • Table 61: Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Discontinued Products 55

1.2 List of Figures

  • Figure 1: Number of Products under Development for Sickle Cell Disease 8
  • Figure 2: Number of Products under Development by Companies, Sickle Cell Disease 9
  • Figure 3: Number of Products under Development by Universities/Institutes, Sickle Cell Disease 11
  • Figure 4: Number of Products under Development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease 15
  • Figure 5: Number of Products under Development by Companies, Vaso-Occlusive Crisis Associated With Sickle Cell Disease 16
  • Figure 6: Number of Products by Top 10 Targets, Sickle Cell Disease 18
  • Figure 7: Number of Products by Stage and Top 10 Targets, Sickle Cell Disease 18
  • Figure 8: Number of Products by Top 10 Mechanism of Actions, Sickle Cell Disease 20
  • Figure 9: Number of Products by Stage and Top 10 Mechanism of Actions, Sickle Cell Disease 20
  • Figure 10: Number of Products by Routes of Administration, Sickle Cell Disease 22
  • Figure 11: Number of Products by Stage and Routes of Administration, Sickle Cell Disease 22
  • Figure 12: Number of Products by Top 10 Molecule Types, Sickle Cell Disease 23
  • Figure 13: Number of Products by Stage and Top 10 Molecule Types, Sickle Cell Disease 24
  • Figure 14: Number of Products by Targets, Vaso-Occlusive Crisis Associated With Sickle Cell Disease 25
  • Figure 15: Number of Products by Stage and Targets, Vaso-Occlusive Crisis Associated With Sickle Cell Disease 25
  • Figure 16: Number of Products by Mechanism of Actions, Vaso-Occlusive Crisis Associated With Sickle Cell Disease 26
  • Figure 17: Number of Products by Stage and Mechanism of Actions, Vaso-Occlusive Crisis Associated With Sickle Cell Disease 27
  • Figure 18: Number of Products by Routes of Administration, Vaso-Occlusive Crisis Associated With Sickle Cell Disease 28
  • Figure 19: Number of Products by Stage and Routes of Administration, Vaso-Occlusive Crisis Associated With Sickle Cell Disease 28
  • Figure 20: Number of Products by Molecule Types, Vaso-Occlusive Crisis Associated With Sickle Cell Disease 29
  • Figure 21: Number of Products by Stage and Molecule Types, Vaso-Occlusive Crisis Associated With Sickle Cell Disease 30
Back to Top